Evidence map›Paper›PMID 39971975›Full record

ArticleScientific reports2025

Neuroprotective effect of NSCs-derived extracellular vesicles in Parkinson's disease models.

Mercyleidi Díaz Reyes, Sabrina Gatti, Susana Delgado Ocaña, Hugo H Ortega, Claudia Banchio

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. GABA-Induced Exosomes Improve Memory Impairment in Aged Mice.International journal of molecular sciences · 2026
    Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mercyleidi Díaz ReyesLaboratorio de Biología Molecular y Celular de Lípidos, Instituto de Biología Molecular y Celular de Rosario (IBR-CONICET) Ocampo y Esmeralda, Predio CONICET and Departamento de Ciencias Biológicas, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, 2000, Rosario, Argentina.
Sabrina GattiLaboratorio de Biología Molecular y Celular de Lípidos, Instituto de Biología Molecular y Celular de Rosario (IBR-CONICET) Ocampo y Esmeralda, Predio CONICET and Departamento de Ciencias Biológicas, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, 2000, Rosario, Argentina.
Susana Delgado OcañaLaboratorio de Biología Molecular y Celular de Lípidos, Instituto de Biología Molecular y Celular de Rosario (IBR-CONICET) Ocampo y Esmeralda, Predio CONICET and Departamento de Ciencias Biológicas, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, 2000, Rosario, Argentina.
Hugo H OrtegaCentro de Medicina Comparada, ICiVet-Litoral, Universidad Nacional del Litoral-CONICET, 3080, Esperanza, Santa Fe, Argentina.
Claudia BanchioLaboratorio de Biología Molecular y Celular de Lípidos, Instituto de Biología Molecular y Celular de Rosario (IBR-CONICET) Ocampo y Esmeralda, Predio CONICET and Departamento de Ciencias Biológicas, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, 2000, Rosario, Argentina. banchio@ibr-conicet.gov.ar.

Funding

Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación PICT 2019-01073
6 · The paper itself

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by both motor and non-motor symptoms, caused by the degeneration and loss of dopaminergic neurons in the substantia nigra. Current therapies are limited to symptom management, unable to prevent neuronal loss or halt the progression of the disease. A significant limitation to more effective treatments is the difficulty of crossing the blood-brain barrier (BBB). Extracellular vesicles (EVs) communication plays a crucial role in several physiological processes within the nervous system. Notably, EVs have the unique ability to cross the BBB, making them a highly promising vehicle for delivering therapeutic agents directly to the brain. Given the rising prevalence of PD, the need for therapies that prevent neuronal death and promote cell survival is urgent. This study explores the potential of neural stem cell-derived extracellular vesicles (NSC-EVs) using two in vitro models of PD. Our findings demonstrate that NSC-EVs significantly enhance the survival of dopaminergic neurons by reducing apoptosis and showing strong neuroprotective effects. Notably, the natural extracellular vesicles used in this study are enriched with Catalase, a potent scavenger protein with antioxidant properties. This natural enrichment further strengthens their neuroprotective capacity, enabling them to mitigate oxidative stress and protect vulnerable neurons. The use of such naturally enriched extracellular vesicles represents a promising approach for developing innovative therapies to effectively combat Parkinson's disease.

Indexed as

Extracellular VesiclesNeural Stem CellsNeuroprotective AgentsParkinson DiseaseAnimalsApoptosisBlood-Brain BarrierCatalaseCell SurvivalDisease Models, AnimalDopaminergic NeuronsHumansMiceNeuroprotectionOxidative StressCatalaseNeuroprotective Agents

Identifiers

PMID39971975
PMCPMC11839983

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.